Herpes simplex virus-2 and HIV among noninjecting drug users in New York City
Herpes simplex virus-2 and HIV among noninjecting drug users in New York City
复制标题
DOI：
10.1097/olq.0b013e3180ca9647
复制
发表时间：
2007-11-01
影响因子：
3.1
通讯作者：
Friedman, Samuel R.
中科院分区：
文献类型：
--
作者：
Des Jarlais, Don C.;Hagan, Holly;Friedman, Samuel R.
目的：研究纽约市非注射海洛因和可卡因使用者中单纯疱疹病毒2型（HSV-2）血清阳性率与人类免疫缺陷病毒（HIV）血清阳性率之间的关系。方法：从纽约市的一个戒毒项目中招募了462名非注射可卡因和海洛因使用者。吸食快克可卡因、鼻内使用海洛因和鼻内使用可卡因是最常见的药物使用类型。结果：HIV感染率为19%（95% CI 15%~ 22%），HSV-2阳性率为60%（95% CI 55%~ 64%）。HSV-2和HIV之间关联的调整风险比为1.9（95%CI 1.21%-2.98%）。HSV-2和HIV之间的关系是特别强的女性，其中86%的HSV-2血清阳性，23%的HIV血清阳性，和所有的HIV血清阳性也HSV-2 serotonic.Conclusions：HSV-2似乎是一个重要的因素，在非注射可卡因和海洛因使用者在纽约市，特别是女性之间的HIV的性传播。该样本中HSV-2感染引起的HIV感染的估计人群归因风险为38%。应制定管理HSV-2感染的方案，作为非注射吸毒者全面预防艾滋病毒的一部分。
Objective: To examine the relationship between herpes simplex virus 2 (HSV-2) seroprevalence and human immunodeficiency virus (HIV) seroprevallence among noninjecting heroin and cocaine users in New York City.Methods: Four hundred sixty-two noninjecting cocaine and heroin users were recruited from a drug detoxification program in New York City. Smoking crack cocaine, intranasal use of heroin, and intranasal use of cocaine were the most common types of drug use. A structured interview was administered and a serum sample was collected for HIV and HSV testing.Results: HIV prevalence was 19% (95% CI 15%-22%) and HSV-2 seroprevalence was 60% (95% CI 55%-64%). The adjusted risk ratio for the association between HSV-2 and HIV was 1.9 (95% CI 1.21%-2.98%). The relationship between HSV-2 and HIV was particularly strong among females, among whom 86% were HSV-2 seropositive, 23% were HIV seropositive, and all HIV seropositives were also HSV-2 seropositive.Conclusions: HSV-2 appears to be an important factor in sexual transmission of HIV among noninjecting cocaine and heroin users in New York City, especially among females. The estimated population attributable risk for HIV infection attributable to HSV-2 infection in this sample was 38%. Programs to manage HSV-2 infection should be developed as part of comprehensive HIV prevention for noninjecting drug users.